Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer

NCT02273375 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT02273375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02273375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 3
Overall status
Completed
Start date
February 24, 2015
Completion date
September 1, 2026
Enrollment
1,415 (actual)
Sites
271

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer